S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   289.63 (-5.40%)
AAPL   140.50 (-5.86%)
MSFT   253.50 (-4.99%)
FB   192.10 (-5.19%)
GOOGL   2,230.02 (-4.27%)
AMZN   2,129.54 (-7.71%)
TSLA   708.56 (-6.97%)
NVDA   168.13 (-7.50%)
BABA   87.24 (-5.16%)
NIO   15.86 (-4.63%)
AMD   95.96 (-6.35%)
CGC   5.59 (-5.09%)
MU   70.92 (-4.78%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.77 (-5.62%)
DIS   104.00 (-4.27%)
AMC   12.73 (-1.32%)
PFE   50.41 (-1.81%)
PYPL   77.09 (-3.34%)
NFLX   177.18 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   289.63 (-5.40%)
AAPL   140.50 (-5.86%)
MSFT   253.50 (-4.99%)
FB   192.10 (-5.19%)
GOOGL   2,230.02 (-4.27%)
AMZN   2,129.54 (-7.71%)
TSLA   708.56 (-6.97%)
NVDA   168.13 (-7.50%)
BABA   87.24 (-5.16%)
NIO   15.86 (-4.63%)
AMD   95.96 (-6.35%)
CGC   5.59 (-5.09%)
MU   70.92 (-4.78%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.77 (-5.62%)
DIS   104.00 (-4.27%)
AMC   12.73 (-1.32%)
PFE   50.41 (-1.81%)
PYPL   77.09 (-3.34%)
NFLX   177.18 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   289.63 (-5.40%)
AAPL   140.50 (-5.86%)
MSFT   253.50 (-4.99%)
FB   192.10 (-5.19%)
GOOGL   2,230.02 (-4.27%)
AMZN   2,129.54 (-7.71%)
TSLA   708.56 (-6.97%)
NVDA   168.13 (-7.50%)
BABA   87.24 (-5.16%)
NIO   15.86 (-4.63%)
AMD   95.96 (-6.35%)
CGC   5.59 (-5.09%)
MU   70.92 (-4.78%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.77 (-5.62%)
DIS   104.00 (-4.27%)
AMC   12.73 (-1.32%)
PFE   50.41 (-1.81%)
PYPL   77.09 (-3.34%)
NFLX   177.18 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   289.63 (-5.40%)
AAPL   140.50 (-5.86%)
MSFT   253.50 (-4.99%)
FB   192.10 (-5.19%)
GOOGL   2,230.02 (-4.27%)
AMZN   2,129.54 (-7.71%)
TSLA   708.56 (-6.97%)
NVDA   168.13 (-7.50%)
BABA   87.24 (-5.16%)
NIO   15.86 (-4.63%)
AMD   95.96 (-6.35%)
CGC   5.59 (-5.09%)
MU   70.92 (-4.78%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.77 (-5.62%)
DIS   104.00 (-4.27%)
AMC   12.73 (-1.32%)
PFE   50.41 (-1.81%)
PYPL   77.09 (-3.34%)
NFLX   177.18 (-7.02%)
NASDAQ:ERYP

ERYTECH Pharma (ERYP) Stock Forecast, Price & News

$1.10
-0.03 (-2.65%)
(As of 05/18/2022 03:59 PM ET)
Add
Compare
Today's Range
$1.10
▼
$1.11
50-Day Range
$1.09
▼
$1.90
52-Week Range
$1.06
▼
$9.50
Volume
405 shs
Average Volume
2.62 million shs
Market Capitalization
$34.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.14
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive ERYP News and Ratings via Email

Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter.

ERYTECH Pharma logo

About ERYTECH Pharma

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.

Headlines

May 17, 2022 | finanznachrichten.de
Erytech Pharma S.A.: ERYTECH to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 | finance.yahoo.com
ERYTECH to Present at the H.C. Wainwright Global Investment Conference
May 13, 2022 | seekingalpha.com
ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2022 Results - Earnings Call Transcript
May 13, 2022 | finance.yahoo.com
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2022
May 13, 2022 | americanbankingnews.com
-$0.67 EPS Expected for ERYTECH Pharma S.A. (NASDAQ:ERYP) This Quarter
May 12, 2022 | nz.finance.yahoo.com
ERYTECH Provides Business and Financial Update for the First Quarter of 2022
May 12, 2022 | finanznachrichten.de
Erytech Pharma S.A.: ERYTECH Provides Business and Financial Update for the First Quarter of 2022
May 12, 2022 | seekingalpha.com
Erytech Pharma reports Q1 results
May 12, 2022 | finance.yahoo.com
ERYTECH Provides Business and Financial Update for the First Quarter of 2022
May 3, 2022 | americanbankingnews.com
ERYTECH Pharma (NASDAQ:ERYP) Lowered to "Hold" at Zacks Investment Research
April 28, 2022 | finance.yahoo.com
ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar
April 27, 2022 | seekingalpha.com
Nkarta, ERYTECH Pharma top healthcare gainers; Eliem, Clarus lead losers' pack
April 25, 2022 | investorplace.com
Why Is ERYTECH Pharma (ERYP) Stock Up Today?
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ERYP
Previous Symbol
CUSIP
N/A
CIK
1624422
Web
www.erytech.com
Phone
(347) 874-4438
Fax
33-4-78-75-56-29
Employees
196
Year Founded
N/A

Sales & Book Value

Annual Sales
$4.95 million
Price / Sales
6.89
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.87 per share
Price / Book
1.26

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.67
Current Ratio
2.00
Quick Ratio
2.00

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
31,020,000
Free Float
N/A
Market Cap
$34.12 million
Optionable
Not Optionable

Company Calendar

Today
5/18/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

0.90 out of 5 stars

Medical Sector

1281st out of 1,426 stocks

Biological Products, Except Diagnostic Industry

195th out of 210 stocks

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













ERYTECH Pharma (NASDAQ:ERYP) Frequently Asked Questions

Is ERYTECH Pharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ERYTECH Pharma in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ERYTECH Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ERYP, but not buy additional shares or sell existing shares.
View analyst ratings for ERYTECH Pharma or view top-rated stocks.

Are investors shorting ERYTECH Pharma?

ERYTECH Pharma saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 618,700 shares, an increase of 105.8% from the April 15th total of 300,600 shares. Based on an average daily volume of 904,000 shares, the short-interest ratio is presently 0.7 days.
View ERYTECH Pharma's Short Interest.

Who are ERYTECH Pharma's key executives?
ERYTECH Pharma's management team includes the following people:
  • Mr. Gil Beyen BVBA, CEO & Director (Age 60, Pay $640.18k)
  • Mr. Eric Soyer Ph.D., CFO, COO & Deputy GM (Age 56, Pay $393.87k)
  • Dr. Jérôme Bailly Pharm.D., Deputy GM of Operations, Chief Quality Officer & Qualified Person (Age 43, Pay $247.8k)
  • Dr. Stewart Craig, Chief Technical Officer (Age 60)
  • Naomi Eichenbaum, Director Investor Relations
  • Mr. Brian Schwab, Chief Legal Officer & Gen. Counsel (Age 57)
  • Ms. Anne-Cécile Fumey, HR Director (Age 47)
  • Dr. Iman El-Hariry M.D., Ph.D., Chief Medical Officer (Age 62)
  • Dr. Philip L. Lorenzi, Consultant & Member of Scientific Board
  • Prof. Eric Raymond M.D., Ph.D., Consultant & Member of Scientific Board
What other stocks do shareholders of ERYTECH Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ERYTECH Pharma investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Sesen Bio (SESN), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE), Gilead Sciences (GILD), MEI Pharma (MEIP), Verastem (VSTM) and ACADIA Pharmaceuticals (ACAD).

When did ERYTECH Pharma IPO?

(ERYP) raised $125 million in an initial public offering on Friday, November 10th 2017. The company issued 5,300,000 shares at a price of $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager.

What is ERYTECH Pharma's stock symbol?

ERYTECH Pharma trades on the NASDAQ under the ticker symbol "ERYP."

Who are ERYTECH Pharma's major shareholders?

ERYTECH Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ERYTECH Pharma?

Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ERYTECH Pharma's stock price today?

One share of ERYP stock can currently be purchased for approximately $1.10.

How much money does ERYTECH Pharma make?

ERYTECH Pharma has a market capitalization of $34.12 million and generates $4.95 million in revenue each year.

How many employees does ERYTECH Pharma have?

ERYTECH Pharma employs 196 workers across the globe.

What is ERYTECH Pharma's official website?

The official website for ERYTECH Pharma is www.erytech.com.

How can I contact ERYTECH Pharma?

ERYTECH Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at (347) 874-4438, via email at [email protected], or via fax at 33-4-78-75-56-29.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.